Söndag 19 Oktober | 00:10:38 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-26 08:40 Bokslutskommuniké 2025
2025-11-20 14:30 Kvartalsrapport 2025-Q3
2025-08-21 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2025-05-22 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-02-27 - Bokslutskommuniké 2024
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2024-05-23 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2024-02-05 - Extra Bolagsstämma 2024
2023-11-23 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-06-15 - Split COEGIN 100:1
2023-05-26 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2023-05-25 - Årsstämma
2023-05-25 - Kvartalsrapport 2023-Q1
2023-02-27 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2022-05-19 - Årsstämma
2022-05-19 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - Årsstämma
2021-05-21 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2021-05-20 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-09-29 - Extra Bolagsstämma 2020
2020-08-28 - Kvartalsrapport 2020-Q2
2020-04-15 - Inlösen COEGIN 0.1
2020-04-03 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2020-04-02 - Årsstämma
2020-02-21 - Bokslutskommuniké 2019
2019-11-23 - Kvartalsrapport 2019-Q3
2019-09-09 - Extra Bolagsstämma 2019
2019-08-24 - Kvartalsrapport 2019-Q2
2019-06-18 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2019-06-17 - Årsstämma
2019-03-16 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-08-24 - Kvartalsrapport 2018-Q2
2018-06-20 - Årsstämma
2018-06-07 - X-dag ordinarie utdelning COEGIN 0.00 SEK
2018-02-23 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriBioteknik
Coegin Pharma är ett svenskt bioteknikföretag med dermakosmetiska projekt för hårtillväxt och hudpigmentering, samt läkemedelskandidater för behandling av hjärtinfarkt och leukemi. Gemensamt för projekten är att de har sin grund i patenterade teknologiplattformar och samarbeten med forskare och akademiker internationellt. Coegin Pharma har sitt huvudkontor i Lund.
2025-10-17 17:05:00

Coegin Pharma AB ("Coegin" or "the Company") has entered a collaboration with Hårklinikken, a global actor in premium, science-driven hair and scalp health, through the signing of a non-exclusive limited purchase order. This represents a major step in the international commercialization of Follicopeptide® - Coegin's cutting-edge, clinically supported innovation for hair growth. Hårklinikkens premium position with strategically placed top-class clinics combined with the company's deep science-based knowledge in the hair growth field makes them an ideal partner. 

Coegin and Hårklinikken initiates a collaboration to bring Follicopeptide to a premium audience
Hårklinikken is a renowned clinic and product brand with more than 33 years of research and clinical experience, offering customized treatments that combine botanicals, clinically tested ingredients, and advanced expertise. With flagship clinics in Beverly Hills (US), New York City (US), Dubai (UAE), Reykjavik (Isl), Copenhagen (DK) and Aarhus (DK), as well as 20 years of experience in virtual consultations with clients from seven continents, Hårklinikken is ideally positioned to introduce Follicopeptide to discerning, premium customers worldwide.

By combining Coegin's breakthrough science with Hårklinikken's unmatched reputation, clinical credibility, and direct customer reach, the collaboration creates a powerful platform for international market expansion.

Hårklinikken will launch the first Follicopeptide-based product under Hårklinikkens label starting in early 2026. The signing of this purchaseorder withHårklinikkenas a selectedlaunch partner follows Coegin's broader launch strategy to accelerate market entry.

Comments from management
Jens Eriksson, CEO of Coegin Pharma, comments:
"Partnering with Hårklinikken, a premium actor in hair and scalp health, is a breakthrough milestone for Coegin. Hårklinikken's decades of clinical expertise, global reputation, and unmatched customer trust make them an ideal partner to launch Follicopeptide. Together, we are ready to bring real science and meaningful results to premium consumers."

Lars Skjøth, Founder & Head of R&D of Hårklinikken, comments:
"At Hårklinikken, we have always been committed to combining science, nature, and individual care to deliver transformative results. We are excited to introduce this cutting-edge solution to our international clientele and strengthen our shared mission of helping people regain their confidence through healthier, stronger hair."

Dr Vasiloudes, board certified dermatologist/Ph.d., CSO of Hårklinikken, adds:
"Coegin Pharma's Follicopeptide stands out as a unique innovation backed by strong science and clinical evidence."    

For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: [email protected] 

This information is information that Coegin Pharma AB is obliged to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was provided, through the contact person mentioned above, for publication on October 17, 2025, at 17:05 CET.

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercialising its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.

Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

More information - including subscription to company updates and links to social media - is available at coeginpharma.com 

About Hårklinikken
Hårklinikken is a premium, science-driven clinic and product brand dedicated to hair and scalp health. With over 33 years of research, they combine customized treatment methods with botanicals, clinically tested ingredients, and advanced expertise to deliver outstanding results. With flagship clinics in Dubai, Beverly Hills, New York City, Reykjavik, Copenhagen and Aarhus Hårklinikken proves its global reach and prestige. Known for modern design, expert teams, and world-class service, Hårklinikken is a trusted partner for clients seeking proven, individualized solutions for healthier hair.

More information is available at harklinikken.com